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Background
The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embo-
lism is controversial.
Methods
In a randomized, double-blind trial, we compared tenecteplase plus heparin with 
placebo plus heparin in normotensive patients with intermediate-risk pulmonary 
embolism. Eligible patients had right ventricular dysfunction on echocardiography 
or computed tomography, as well as myocardial injury as indicated by a positive test 
for cardiac troponin I or troponin T. The primary outcome was death or hemody-
namic decompensation (or collapse) within 7 days after randomization. The main 
safety outcomes were major extracranial bleeding and ischemic or hemorrhagic 
stroke within 7 days after randomization.
Results
Of 1006 patients who underwent randomization, 1005 were included in the intention-
to-treat analysis. Death or hemodynamic decompensation occurred in 13 of 506 pa-
tients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in the 
placebo group (odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; P = 0.02). Be-
tween randomization and day 7, a total of 6 patients (1.2%) in the tenecteplase group 
and 9 (1.8%) in the placebo group died (P = 0.42). Extracranial bleeding occurred in 
32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo 
group (P<0.001). Stroke occurred in 12 patients (2.4%) in the tenecteplase group and 
was hemorrhagic in 10 patients; 1 patient (0.2%) in the placebo group had a stroke, 
which was hemorrhagic (P = 0.003). By day 30, a total of 12 patients (2.4%) in the ten-
ec teplase group and 16 patients (3.2%) in the placebo group had died (P = 0.42).
Conclusions
In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented 
hemodynamic decompensation but increased the risk of major hemorrhage and stroke. 
(Funded by the Programme Hospitalier de Recherche Clinique in France and others; 
PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.)
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A cute pulmonary embolism occurs frequently and may cause death or serious disability.1 Case fatality rates vary wide-
ly,2,3 but approximately 10% of all patients with 
acute pulmonary embolism die within 3 months 
after the diagnosis.4,5
Acute right ventricular pressure overload at 
diagnosis is an important determinant of the 
severity and early clinical outcome of pulmonary 
embolism.6 High-risk pulmonary embolism7 is 
characterized by overt hemodynamic instability 
and warrants immediate advanced therapy, in-
cluding consideration of fibrinolysis. In contrast, 
for patients presenting without systemic hypo-
tension or hemodynamic compromise, standard 
anticoagulation is generally considered adequate 
treatment.8 However, patients who have acute 
right ventricular dysfunction and myocardial in-
jury without overt hemodynamic compromise 
may be at intermediate risk for an adverse early 
outcome.7,9 These patients (referred to hence-
forth as patients with intermediate-risk pulmo-
nary embolism) may also be candidates for early 
reperfusion therapy.10
Randomized clinical trials that test fibrino-
lytic agents versus heparin alone in patients with 
acute pulmonary embolism have enrolled, in 
total, fewer than 1000 patients over the past 
40 years.11 Although these drugs have been 
shown to rapidly improve hemodynamic vari-
ables,12 their effects on the clinical outcome, 
particularly in patients without hemodynamic 
instability at presentation, have not been deter-
mined. The Pulmonary Embolism Thrombolysis 
(PEITHO) trial was designed to investigate the 
clinical efficacy and safety of fibrinolytic ther-
apy with a single-bolus injection of tenecteplase, 
in addition to standard anticoagulation therapy 
with heparin, in normotensive patients with 
acute pulmonary embolism and an intermediate 
risk of an adverse outcome.
Me thods
Study design
We performed a multicenter, double-blind, placebo-
controlled randomized trial.13 The trial was ini-
tiated by the investigators and sponsored by 
Direction de la Recherche Clinique at Assistance 
Publique–Hôpitaux de Paris, a consortium of uni-
versity hospitals in Paris. Trial funding was pro-
vided by Programme Hospitalier de Recherche 
Clinique in France, by the Federal Ministry of 
Education and Research in Germany, and by a 
grant from Boehringer Ingelheim. None of the 
trial funders had any role in the design or con-
duct of the trial, the analysis of the data, or the 
preparation of the manuscript.
The trial protocol was written by three of the 
academic principal investigators and reviewed, 
modified, and approved by the trial steering 
committee (see the Supplementary Appendix, 
available with the full text of this article at 
NEJM.org). The final protocol was approved by 
the ethics review board of each study site. An 
independent data and safety monitoring board 
periodically reviewed the study outcomes. A 
clinical research organization appointed by the 
sponsor was responsible for data collection and 
monitoring at the participating sites. Data were 
gathered with the use of electronic case report 
forms and kept at Unité de Recherche Clinique 
(Lariboisière Hospital, Université Paris 7) under 
the supervision of the trial statistician, who in-
dependently performed all statistical analyses 
before the code for concealing the study assign-
ments was broken.
The principal investigators had unrestricted 
access to the data after the database was locked. 
The two cochairs of the steering committee and 
the trial statistician wrote the first draft of the 
manuscript. The members of the steering com-
mittee were involved in the analysis of the data; 
reviewed, amended, and approved the early ver-
sion of the manuscript; and made the decision to 
submit the manuscript for publication. All mem-
bers of the steering committee vouch for the 
integrity and completeness of the data and for 
the fidelity of this report to the trial protocol, 
available at NEJM.org. Assistance Publique–
Hopitaux de Paris and Boehringer Ingelheim 
signed a mutual confidentiality agreement on 
initiation of the study, and an early version of the 
manuscript was sent to a representative of Boeh-
ringer Ingelheim before submission.
Patients
Patients were eligible for the study if they met all 
the following criteria: an age of 18 years or older, 
objectively confirmed acute pulmonary embolism 
with an onset of symptoms 15 days or less before 
randomization, right ventricular dysfunction con-
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firmed by echocardiography or spiral computed 
tomography (CT) of the chest, and myocardial 
injury confirmed by a positive test for troponin I 
or troponin T.13 The full inclusion and exclusion 
criteria for the study, including the criteria for 
right ventricular dysfunction, are listed in the 
Supplementary Appendix. Written informed con-
sent was obtained from all patients before ran-
domization.
Randomization and Treatment
Eligible patients underwent central randomiza-
tion with the use of a computerized Internet-
based system. Randomization was stratified by 
center and, within centers, was performed in 
blocks to ensure balanced distribution of the 
treatment groups. We required that randomiza-
tion be performed within 2 hours after the inves-
tigator became aware of the presence of both 
right ventricular dysfunction (by receiving the 
echocardiography or CT report) and myocardial 
injury (by receiving a report of a positive cardiac 
troponin test).
Patients who were assigned to undergo fibri-
nolysis received a single weight-based intravenous 
bolus (given over a period of 5 to 10 seconds) of 
the fibrinolytic agent tenecteplase. The dose 
ranged from 30 mg to 50 mg, depending on 
body weight (Table S1 in the Supplementary Ap-
pendix).13 Patients assigned to placebo were given 
a single intravenous bolus of the same volume 
and appearance as the bolus of tenecte plase.
The administration of unfractionated heparin 
was started as an intravenous bolus immediately 
after randomization in both groups; the bolus 
was not administered to patients who had already 
received an intravenous bolus or infusion of un-
fractionated heparin. The initial bolus of unfrac-
tionated heparin was also omitted in patients 
receiving a therapeutic dose of low-molecular-
weight heparin or fondaparinux, and the start of 
the infusion was delayed until 12 hours after the 
last injection of low-molecular-weight heparin or 
until 24 hours after the last injection of fonda-
parinux. The heparin infusion rate was adjusted 
to achieve and maintain an activated partial-
thromboplastin time that was 2.0 to 2.5 times 
the upper limit of the normal range, correspond-
ing to therapeutic heparin levels (equivalent to 
factor Xa inhibition of 0.3 to 0.7 IU per milliliter). 
The use of anticoagulant agents other than un-
fractionated heparin was not allowed until 48 
hours after randomization.
Follow-Up and Outcome Assessment
All patients were followed for 30 days and were 
evaluated for death, hemodynamic decompensa-
tion (or collapse), bleeding, stroke, recurrent pul-
monary embolism, and serious adverse events. 
All efficacy and safety outcomes were adjudicat-
ed by an independent clinical-events committee 
whose members were unaware of the treatment-
group assignments.
The primary efficacy outcome was the clini-
cal composite of death from any cause or hemo-
dynamic decompensation (or collapse) within 
7 days after randomization. The secondary out-
comes included death within 7 days after ran-
domization, hemodynamic decompensation with-
in 7 days, confirmed symptomatic recurrence of 
pulmonary embolism within 7 days, death with-
in 30 days, and major adverse events within 30 
days.13 Safety outcomes were defined as ische-
mic or hemorrhagic stroke (including hemor-
rhagic conversion of ischemic stroke) within 
7 days after randomization, extracranial major 
(moderate or severe) bleeding within 7 days, and 
serious adverse events within 30 days. The defi-
nitions of hemodynamic decompensation and 
bleeding events are provided in the Supplemen-
tary Appendix.
Statistical Analysis
The main efficacy and safety analyses were based 
on all events that occurred in the intention-to-
treat population, defined as all patients who un-
derwent randomization and who signed the in-
formed consent form. In addition, analysis of 
safety outcomes was performed in the safety 
population, which was defined as all patients 
who received the study drug. The primary effi-
cacy outcome was analyzed by means of a two-
sided chi-square test of proportions. A similar 
analysis was performed for each of the secondary 
outcomes; all results were for the intention-to-
treat population. All tests were performed with 
the use of SAS software, version 9.2 (SAS Insti-
tute). Prespecified subgroup analyses included 
age (≤75 years vs. >75 years), sex, and country of 
recruitment. Details of the sample-size estima-
tion and the interim analyses are given in the 
Supplementary Appendix.
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R esult s
Patients
From November 2007 through July 2012, a total 
of 1006 patients were enrolled at 76 sites in 13 
countries. Of these patients, 506 were randomly 
assigned to treatment with tenecteplase plus un-
fractionated heparin, and 500 were randomly as-
signed to placebo plus unfractionated heparin 
(Fig. S1 in the Supplementary Appendix). The 
signed informed consent form of 1 patient in the 
placebo group could not be found, and this pa-
tient was therefore excluded from all data analy-
ses; thus, the intention-to-treat population con-
sisted of 1005 patients. All but 5 patients received 
the assigned study drug.
The demographic data, clinical status at base-
line, and medical history of the patients were 
well matched between the two treatment groups 
(Table 1). The median age in the study popula-
Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Tenecteplase
(N = 506)
Placebo
(N = 499)
Demographic data
Age — yr
Mean 66.5±14.7 65.8±15.9
Median (interquartile range) 70.0 (59.0–77.0) 70.0 (57.0–78.0)
Male sex — no. (%) 242 (47.8) 231 (46.3)
Mean weight — kg 82.5±17.9 82.6±18.2
Clinical status
Systolic blood pressure — mm Hg 130.8±18.3 131.3±18.5
Missing data — no. (%) 3 (0.6) 4 (0.8)
Heart rate — beats per min 94.5±17.1 92.3±16.7
Missing data — no. (%) 6 (1.2) 7 (1.4)
Respiratory rate — breaths per min 21.8±5.8 21.6±5.7
Missing data — no. (%) 95 (18.8) 107 (21.4)
Oxygen treatment — no. (%) 436 (86.2) 421 (84.4)
Medical history
Chronic pulmonary disease — no. (%) 26 (5.1) 34 (6.8)
Missing data 6 (1.2) 6 (1.2)
Chronic heart failure — no. (%) 21 (4.2) 26 (5.2)
Missing data 5 (1.0) 7 (1.4)
Previous venous thromboembolism — no. (%) 126 (24.9) 147 (29.5)
Missing data 2 (0.4) 9 (1.8)
Active cancer — no. (%) 41 (8.1) 32 (6.4)
Missing data 20 (4.0) 20 (4.0)
Surgery or major trauma in previous month — no. (%) 31 (6.1) 27 (5.4)
Missing data 1 (0.2) 4 (0.8)
Immobilization — no. (%) 55 (10.9) 56 (11.2)
Missing data 5 (1.0) 9 (1.8)
Estrogen use — no. (%) 30 (5.9) 33 (6.6)
Missing data 7 (1.4) 5 (1.0)
* Plus–minus values are means ±SD. Between-group differences in the characteristics listed here were not significant;  
for heart rate, P = 0.05.
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tion was 70 years. All patients were normoten-
sive at randomization. In the vast majority of 
cases, the diagnosis of pulmonary embolism was 
confirmed by CT pulmonary angiography (Ta-
ble 2). Right ventricular dysfunction was diag-
nosed by echocardiography or CT in all cases, 
and myocardial injury was confirmed with a test 
for cardiac troponin I or troponin T in all but 
9 patients. Low-molecular-weight heparin or fon-
daparinux was administered before randomiza-
tion in 303 patients (30.1%), and the remaining 
patients received unfractionated heparin before 
randomization or at the time of randomization. 
The proportions of patients in whom the activat-
ed partial-thromboplastin time was within, above, 
and below the target range initially and within 
the first 24 hours after the administration of the 
study drug are shown in Table S2 in the Supple-
mentary Appendix.
Efficacy Outcomes
Between randomization and day 7, the primary 
efficacy outcome occurred in 13 patients (2.6%) 
in the tenecteplase group as compared with 28 
patients (5.6%) in the placebo group (odds ratio, 
0.44; 95% confidence interval [CI], 0.23 to 0.87; 
P = 0.02) (Table 3). Six patients (1.2%) in the tenec-
teplase group and 9 patients (1.8%) in the place-
bo group died between randomization and day 7 
(P = 0.42), and hemodynamic decompensation or 
collapse occurred in 8 patients (1.6%) in the ten-
ec teplase group and 25 patients (5.0%) in the pla-
cebo group (P = 0.002). Persistent hypotension or 
a drop in blood pressure was recorded in 8 pa-
tients in the tenecteplase group and 18 patients 
in the placebo group, catecholamines were ad-
ministered to 3 patients in the tenecteplase group 
and 14 patients in the placebo group, and 1 patient 
in the tenecteplase group and 5 patients in the 
placebo group required cardiopulmonary resus-
citation. The causes of death at day 7 are shown 
in Table S3 in the Supplementary Appendix.
Eight patients in the tenecteplase group re-
quired mechanical ventilation, as compared with 
15 patients in the placebo group. More patients 
in the placebo group than in the tenecteplase 
group underwent open-label rescue fibrinolysis 
(Table 3); in accordance with the protocol, this 
treatment was administered only after the primary 
outcome had occurred, with the exception of nine 
patients. The age, treatment assignment (tenec-
teplase or placebo), and outcomes for all patients 
who underwent rescue fibrinolysis are shown in 
Table S4 in the Supplementary Appendix.
By day 30 after randomization, 12 patients 
(2.4%) in the tenecteplase group had died, as 
compared with 16 patients (3.2%) in the placebo 
group (P = 0.42) (Table 3). The causes of death at 
day 30 are shown in Table S3 in the Supplemen-
tary Appendix.
Safety Outcomes
Major bleeding, as defined according to the crite-
ria of the International Society on Thrombosis 
and Haemostasis,14 occurred between random-
ization and day 7 in 58 patients (11.5%) in the 
tenecteplase group and 12 patients (2.4%) in the 
placebo group (Table 4). Major extracranial bleed-
ing occurred in 32 patients (6.3%) in the tenec te-
plase group and 6 patients (1.2%) in the placebo 
group (P<0.001). (Data for the safety population 
are provided in Table S5 in the Supplementary 
Appendix.)
Overall, 12 patients (2.4%) in the tenecteplase 
Table 2. Diagnostic Evaluation and Initial Management.*
Characteristic
Tenecteplase
(N = 506)
Placebo
(N = 499)
no. (%)
Confirmation of pulmonary embolism
CT 480 (94.9) 472 (94.6)
Ventilation–perfusion lung 
scanning
31 (6.1) 35 (7.0)
Pulmonary angiography 6 (1.2) 8 (1.6)
Confirmation of right ventricular 
dysfunction
Echocardiography 278 (54.9) 255 (51.1)
CT 74 (14.6) 72 (14.4)
Both echocardiography and CT 154 (30.4) 172 (34.5)
Confirmation of myocardial injury
Elevated cardiac troponin I 364 (71.9) 361 (72.3)
Elevated cardiac troponin T 164 (32.4) 164 (32.9)
Either troponin I or troponin T 
elevation
502 (99.2) 494 (99.0)
Low-molecular-weight heparin or 
fondaparinux given before 
randomization
170 (33.6) 133 (26.6)
* Between-group differences in the characteristics listed here were not signifi-
cant except for low-molecular-weight heparin or fondaparinux given before 
randomization (P = 0.02).
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Table 3. Efficacy Outcomes.*
Outcome
Tenecteplase
(N = 506)
Placebo
(N = 499)
Odds Ratio 
(95% CI) P Value
Primary outcome — no. (%) 13 (2.6) 28 (5.6) 0.44 (0.23–0.87) 0.02
Death from any cause 6 (1.2) 9 (1.8) 0.65 (0.23–1.85) 0.42
Hemodynamic decompensation 8 (1.6) 25 (5.0) 0.30 (0.14–0.68) 0.002
Time between randomization and primary 
efficacy outcome — days
1.54±1.71 1.79±1.60
Recurrent pulmonary embolism between 
randomization and day 7 — no. (%)
1 (0.2) 5 (1.0) 0.20 (0.02–1.68) 0.12
Fatal 0 3 (0.6)
Nonfatal 1 (0.2) 2 (0.4)
Other in-hospital complications  
and procedures — no. (%)
Mechanical ventilation 8 (1.6) 15 (3.0)
Surgical embolectomy 1 (0.2) 2 (0.4)
Catheter thrombus fragmentation 1 (0.2) 0 (0.0)
Vena cava interruption 5 (1.0) 1 (0.2)
Thrombolytic treatment other than study 
medication
4 (0.8) 23 (4.6)
Death from any cause between randomization 
and day 30 — no. (%)
12 (2.4) 16 (3.2) 0.73 (0.34–1.57) 0.42
Patient still hospitalized at day 30 — no. (%) 59 (11.7) 50 (10.0)
Rehospitalization between randomization  
and day 30 — no. (%)
22 (4.4) 15 (3.0)
* Plus–minus values are means ±SD. Odds ratios and P values are provided for efficacy outcomes that were prespecified 
in the trial protocol.
Table 4. Safety Outcomes in the Intention-to-Treat Population.*
Outcome
Tenecteplase
(N = 506)
Placebo
(N = 499)
Odds Ratio
(95% CI) P Value
no. (%)
Bleeding between randomization and day 7
Major extracranial bleeding 32 (6.3) 6 (1.2) 5.55 (2.3–13.39) <0.001
Minor bleeding 165 (32.6) 43 (8.6)
Major bleeding† 58 (11.5) 12 (2.4)
Stroke between randomization and day 7 12 (2.4) 1 (0.2) 12.10 (1.57–93.39) 0.003
Ischemic stroke 2 (0.4) 0
Hemorrhagic stroke‡ 10 (2.0) 1 (0.2)
Serious adverse events between 
randomization and day 30
55 (10.9) 59 (11.8) 0.91 (0.62–1.34) 0.63
* Odds ratios and P values are provided for efficacy and safety outcomes that were prespecified in the trial protocol.
† Major bleeding was defined according to the criteria of the International Society on Thrombosis and Haemostasis.
‡ Hemorrhagic stroke included hemorrhagic conversion of ischemic stroke.
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group had a stroke within 7 days after random-
ization; in 10 of these patients, the stroke was 
hemorrhagic. By comparison, only 1 patient in 
the placebo group had a stroke (P = 0.003), and it 
was a hemorrhagic stroke (Table 4). The charac-
teristics and 30-day outcomes of all patients who 
had a stroke are shown in Table S6 in the Sup-
plementary Appendix. Six of the 10 patients in 
the tenecteplase group who had a hemorrhagic 
stroke were alive 30 days after randomization, 
corresponding to a case fatality rate of 40%; 
mild or moderate disability persisted in most of 
the survivors.
Patient Subgroups
Prespecified subgroups were defined by age 
(≤75 years vs. >75 years), sex, and country of 
recruitment. The last subgroup analysis was not 
performed because some countries had only a 
small number of patients who would have been 
included.
The primary efficacy outcome and the rate 
of extracranial major bleeding in the prespeci-
fied subgroups of age and sex are shown in 
Figure 1. Among patients who were 75 years of 
age or younger, the primary efficacy outcome 
occurred in 1.7% of the patients assigned to 
tenecteplase and 5.1% of those assigned to pla-
cebo, corresponding to an odds ratio of 0.33 
(95% CI, 0.13 to 0.85) in favor of tenecteplase; 
by comparison, the odds ratio was 0.63 (95% 
CI, 0.24 to 1.66) among patients older than 75 
years of age. However, on the basis of interac-
tion testing, this difference was not significant 
(P = 0.36) (Fig. 1A). Among the patients treated 
with tenecteplase, older patients had a higher 
rate of major extracranial bleeding than did 
younger patients; the difference was not sig-
nificant (P = 0.09). The rates of these efficacy 
and safety outcomes also did not differ signifi-
cantly between men and women. The results of 
additional subgroup analyses of the primary 
1.0 10.0
Placebo BetterTenecteplase Better
Age
≤75 yr
>75 yr
Sex
Male
Female
Tenecteplase
(N=506) Odds Ratio (95% CI)
Placebo
(N=499)Subgroup
Death or Hemodynamic Decompensation
Major Extracranial Bleeding
A
0.33 (0.13–0.85)
0.42 (0.16–1.12)
0.46 (0.18–1.16)
0.1
0.63 (0.24–1.66)
P Value for
Interaction
6/344 (1.7)
7/162 (4.3)
7/242 (2.9)
6/264 (2.3)
17/335 (5.1)
11/164 (6.7)
14/231 (6.1)
14/268 (5.2)
0.36
0.90
no. of events/total no. (%)
1.0 1000.0100.010.0
Placebo BetterTenecteplase Better
Age
≤75 yr
>75 yr
Sex
Male
Female
Tenecteplase
(N=506) Odds Ratio (95% CI)
Placebo
(N=499)Subgroup
B
2.80 (1.00–7.86)
11.49 (2.67–49.53)
2.70 (0.85–8.61)
0.1
20.38 (2.69–154.53)
P Value for
Interaction
14/344 (4.1)  
 18/162 (11.1)
11/242 (4.5)  
21/264 (8.0)  
5/335 (1.5)
1/164 (0.6)
4/231 (1.7)
2/268 (0.7)
0.09
0.13
no. of events/total no. (%)
Figure 1. Efficacy and Safety Outcomes in Prespecified Subgroups.
Panel A shows the primary efficacy outcome (death or hemodynamic decompensation), and Panel B shows a safety outcome (major ex-
tracranial bleeding), both within 7 days after randomization.
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efficacy outcome, which were not prespecified, 
are shown in Figure S2 in the Supplementary 
Appendix.
Discussion
In the PEITHO trial, patients with intermediate-
risk pulmonary embolism who were treated with 
standard anticoagulation had a 5.6% incidence of 
death or hemodynamic decompensation (the pri-
mary efficacy outcome) within the first 7 days 
after randomization. A single-bolus injection of 
the fibrinolytic agent tenecteplase, in a weight-
based dose, resulted in a significantly lower risk 
of the primary outcome (2.6%). Fibrinolytic treat-
ment was associated with a 2.0% rate of hemor-
rhagic stroke and a 6.3% rate of major extracra-
nial hemorrhage.
Normotensive patients with pulmonary em-
bolism may have an elevated risk of early death 
or major complications if they present with right 
ventricular dysfunction or injury to the myocar-
dium as a result of acute pressure overload.6,15-20 
Fibrinolytic treatment promptly reduces pulmo-
nary-artery resistance and pressure,21 and trials 
that included patients with hemodynamic com-
promise,11 as well as recently published epide-
miologic data,22 support its use in patients with 
massive or high-risk pulmonary embolism. In 
contrast, the efficacy of fibrinolytic agents in 
improving the outcome for patients with inter-
mediate-risk pulmonary embolism has remained 
controversial because of the lack of trials of ade-
quate size with a focus on this patient population. 
Our results indicate that prompt fibrinolysis can 
reduce the risk of hemodynamic decompensa-
tion or death in normotensive patients who have 
acute pulmonary embolism with right ventricu-
lar dysfunction, as indicated by echocardiogra-
phy or CT, and myocardial injury, as indicated by 
a positive cardiac troponin test.
In the present trial, the efficacy of throm-
bolysis was mainly driven by the prevention of 
hemodynamic decompensation; the study was not 
powered to detect differences in rates of death, 
which occurred relatively infrequently in the two 
treatment groups. Moreover, our definition of 
hemodynamic decompensation or collapse includ-
ed a persistent, isolated drop in systolic blood 
pressure, which could be of questionable clinical 
significance. Nevertheless, 14 patients with 
hemodynamic decompensation in the placebo 
group needed inotropic support and 5 under-
went cardiopulmonary resuscitation. It is possi-
ble that the prognosis for some of these patients 
would have been worse if they had not been 
closely monitored and promptly treated when 
decompensation occurred; this notion is sup-
ported by the higher rates of death reported in 
noninterventional cohort studies focused on this 
patient population.10
Fibrinolytic treatment is known to carry a 
risk of major bleeding, including intracranial 
hemorrhage. In two analyses of pooled data from 
trials of various fibrinolytic agents and regimens 
in patients with pulmonary embolism, intracra-
nial bleeding rates were 1.8% and 2.2%.23,24 The 
results of the present study, involving single-
bolus tenecteplase, confirm these findings: the 
risk of hemorrhagic stroke was 2.0% among 
hemodynamically stable patients with acute pul-
monary embolism.
In previous studies, increasing age and the 
presence of coexisting conditions have been as-
sociated with a higher risk of bleeding complica-
tions.25 Our findings also suggest that fibrinoly-
sis is associated with a lower risk of bleeding in 
younger patients than in patients over 75 years 
of age, although this difference was not signifi-
cant. In a recently published trial of tenecteplase 
treatment in patients with ST-segment elevation 
myocardial infarction, there were no cases of 
intracranial hemorrhage when the dose was re-
duced by 50% in patients 75 years of age or 
older.26 A reduced-dose strategy might also be 
beneficial in patients with intermediate-risk 
pulmonary embolism and warrants further in-
vestigation.27 An alternative approach, consist-
ing of ultrasound-assisted local administration 
of small doses of a fibrinolytic agent by means 
of a catheter, is currently being investigated 
(ClinicalTrials.gov number, NCT01513759), and 
a recently published randomized trial of this 
approach in 59 patients showed a promising 
safety profile.28
In conclusion, in normotensive patients with 
intermediate-risk pulmonary embolism, the com-
posite primary outcome of early death or hemo-
dynamic decompensation was reduced after 
treatment with a single intravenous bolus of tenec-
teplase. However, tenecteplase was also associ-
ated with a significant increase in the risk of 
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intracranial and other major bleeding. There-
fore, great caution is warranted when consider-
ing fibrinolytic therapy for hemodynamically 
stable patients with pulmonary embolism, right 
ventricular dysfunction, and a positive cardiac 
troponin test.
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